FDA — authorised 6 March 2015
- Application: NDA207500
- Marketing authorisation holder: ASTELLAS
- Local brand name: CRESEMBA
- Indication: CAPSULE — ORAL
- Status: approved
FDA authorised Isavuconazonium sulfate capsules on 6 March 2015
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 6 March 2015; FDA authorised it on 6 March 2015.
ASTELLAS holds the US marketing authorisation.